← All Rallybio CORP filings

Rallybio CORP 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
RLYB
Rallybio CORP
10-Q: Rallybio Reports Q2 2026 Results Amid Merger Activity
Rallybio Corporation filed its Form 10-Q for the quarter ended June 30, 2026, detailing financial results, ongoing merger plans with Avenzo Therapeutics, and operational updates.
NASDAQ
RLYB
Rallybio CORP
10-Q: Rallybio Reports Q3 Net Income, Extends Runway to 2027
Rallybio Corporation achieved net income in Q3 2025 driven by a strategic joint venture sale, extending its cash runway through 2027 while advancing its lead rare disease programs.
NASDAQ
RLYB
Rallybio CORP
10-Q: Rallybio Cuts Losses, Extends Cash Runway to 2027
Rallybio Corporation significantly reduced its net loss and operating expenses in Q2 2025, extending its cash runway into mid-2027, despite discontinuing its RLYB212 program.
NASDAQ
RLYB
Rallybio CORP
10-Q: Rallybio Reports Q1 2025 Financial Results, Provides Business Update
Rallybio announces Q1 2025 financial results, highlighting progress in RLYB116 development and pipeline prioritization.
NASDAQ
RLYB
Rallybio CORP
10-Q: Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Update
Rallybio Corporation released its third quarter 2024 financial results, highlighting progress in its clinical programs and strategic collaborations.
NASDAQ
RLYB
Rallybio CORP
10-Q: Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Update
Rallybio Corporation announced its second quarter 2024 financial results, highlighting progress in its clinical programs and a new collaboration with Johnson & Johnson.
NASDAQ
RLYB
Rallybio CORP
10-Q: Rallybio Reports First Quarter 2024 Results, Prioritizes RLYB212 Development
Rallybio Corporation announced its first quarter 2024 financial results, highlighting a strategic shift to prioritize the development of RLYB212 and a workforce reduction.